Skip to main
PASG
PASG logo

PASSAGE BIO (PASG) Stock Forecast & Price Target

PASSAGE BIO (PASG) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Passage Bio Inc. has demonstrated promising results in its June 2025 interim upliFT-D study, showing a significant increase in the mean cerebrospinal fluid (CSF) PGRN levels from less than 2 ng/mL at baseline to a peak concentration of 25.9 ng/mL, which reflects the durability of Dose 1 therapy over 18 months. The observed plasma neurofilament light chain (NfL) increase of 4% further supports the company’s efforts in addressing critical pathology in neurodegenerative diseases. These encouraging clinical findings position Passage Bio favorably in the genetic medicines sector, particularly for the treatment of rare, monogenic CNS disorders, despite potential competition in the gene therapy landscape.

Bears say

Passage Bio's stock outlook is negatively affected by the potential for delays in clinical development for its pipeline products, PBGM01 and PBFT02, due to unforeseen safety issues and efficacy levels that may fall short of expectations. Additionally, there are significant regulatory risks that could impede progress and market entry, alongside challenges in defending its patents, which could lead to increased competition in the rapidly evolving gene therapy landscape. The uncertainty surrounding long-term treatment durability, particularly in light of previous clinical outcomes such as those observed with LLY's AAV9-based PR007, adds further concerns regarding the company's future performance in this sector.

PASSAGE BIO (PASG) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PASSAGE BIO and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PASSAGE BIO (PASG) Forecast

Analysts have given PASSAGE BIO (PASG) a Strong Buy based on their latest research and market trends.

According to 4 analysts, PASSAGE BIO (PASG) has a Strong Buy consensus rating as of Oct 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $30.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $30.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PASSAGE BIO (PASG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.